TRELEGY is for maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema, and for reducing exacerbations in patients with a history of exacerbations. TRELEGY is NOT indicated for relief of acute bronchospasm or asthma.

contact gsk

1-xxx-xxx-xxxx

For appropriate patients with COPD

LESS TO TAKE. MORE TO TAKE IN.

TRELEGY—the only once-daily triple therapy (ICS/LABA/LAMA) for COPD delivered in a single inhaler

There's more information to take in

with the landmark IMPACT Trial

Discover the latest clinical data from the IMPACT Trial on exacerbations, lung function, and health-related quality of life for your patients with a history of COPD exacerbations

See impact study results

one

inhaler.

once

daily.

one

co-pay.*

*One co-pay is not a guarantee of coverage or lower out-of-pocket costs for patients than alternative treatments. Formulary status and patient out-of-pocket costs may vary, may be up to the prescription’s retail cost, and are subject to change.

one

inhaler.

once

daily.

one

co-pay.*

*One co-pay is not a guarantee of coverage or lower out-of-pocket costs for patients than alternative treatments. Formulary status and patient out-of-pocket costs may vary, may be up to the prescription’s retail cost, and are subject to change.

Simplify the delivery of an

ICS, LABA, and LAMA with once-daily TRELEGY

For patients with COPD, once-daily dosing with TRELEGY may help to simplify triple therapy. TRELEGY does not replace a rescue inhaler. Patients should be provided a short-acting beta2-agonist, such as albuterol, to treat acute symptoms and instructed on how it should be used.

TRELEGY combines three medications in a single inhaler:

An ICS to reduce inflammation

A LABA to increase bronchodilation

A LAMA to reduce bronchoconstriction

Chat with GSK Medical Information to learn more about once-daily TRELEGY

Chat with GSK

Explore more clinical data

on exacerbations, lung function, and health-related quality of life

VIEW CLINICAL TRIALS

For appropriate patients with COPD

on maintenance medication who need improvement in lung function or reduction in exacerbations, TRELEGY offers an ICS, LABA, and LAMA in a single inhaler

VIEW PATIENT PROFILE

Discover TRELEGY ELLIPTA –

our latest innovation in COPD treatment

Contact GSK at 1-XXX-XXX-XXXX to learn more

Stay up-to-date with new information

Get samples for your patients

request samples

Find a TRELEGY representative

Request a rep

Chat